

## Domain Alternation and Active Site Remodeling Are Conserved Structural Features of Ubiquitin E1

Zongyang Lv<sup>‡</sup>, Lingmin Yuan<sup>‡</sup>, James H. Atkison<sup>‡</sup>, Grace Aldana-Masangkay<sup>¶</sup>, Yuan Chen<sup>¶</sup>, & Shaun K. Olsen<sup>‡1</sup>

From the <sup>‡</sup>Department of Biochemistry & Molecular Biology and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425 and the <sup>¶</sup>Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010

Running Title: Domain Alternation and Active Site Remodeling in Uba1

<sup>1</sup>To whom correspondence should be addressed: Shaun K. Olsen, Department of Biochemistry & Molecular Biology, 173 Ashley Ave., MSC 509, Room 501, Charleston, SC 29425, Phone: 843-876-2308, Email: [olsensk@musc.edu](mailto:olsensk@musc.edu)

**Keywords: ubiquitin, E1, adenylation, thioester, domain alternation, x-ray crystallography, structure-function, conformational change, enzyme mechanism, enzyme structure**

### ABSTRACT

E1 enzymes for ubiquitin (Ub) and Ub-like modifiers (Ubls) harbor two catalytic activities that are required for Ub/Ubl activation: adenylation and thioester bond formation. Structural studies of the E1 for the Ubl SUMO revealed a single active site that is transformed by a conformational switch that toggles its competency for catalysis of these two distinct chemical reactions. Although the mechanisms of adenylation and thioester bond formation revealed by SUMO E1 structures are thought to be conserved in Ub E1, there is currently a lack of structural data supporting this hypothesis. Here, we present a structure of *Schizosaccharomyces pombe* Uba1 in which the SCCH domain harboring the catalytic cysteine has undergone a 106 degree rotation that results in a completely different network of intramolecular interactions between the SCCH and adenylation domains, and translocation of the catalytic cysteine 12 Å closer to the Ub C-terminus compared to previous Uba1 structures. SCCH domain alternation is accompanied by conformational changes within the Uba1 adenylation domains that effectively disassemble the adenylation active site. Importantly, the structural and biochemical data suggest that domain alternation and remodeling of the adenylation active site are interconnected and intrinsic structural features of Uba1, and that the overall structural basis for adenylation and

thioester bond formation exhibited by SUMO E1 is indeed conserved in Ub E1. Finally, the mechanistic insights provided by the novel conformational snapshot of Uba1 presented in this study may guide efforts to develop small molecule inhibitors of this critically important enzyme that is an active target for anti-cancer therapeutics.

Ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) play a fundamental role in almost every aspect of eukaryotic biology through their regulation of myriad cellular proteins (1-3). E1 enzymes function as the gatekeepers of Ub/Ubl conjugation cascades by specifically binding and activating their cognate Ub/Ubl in a two-step ATP•Mg-dependent process. Ub/Ubl activation involves adenylation of the Ub/Ubl C-terminus in the first step, followed by nucleophilic attack of the acyl-adenylate by the E1 catalytic cysteine to form a high energy E1~Ub thioester intermediate in the second step (4,5). E1 next recruits E2 conjugating enzymes and transfers Ub/Ubl to the E2 catalytic cysteine in a process termed E1-E2 thioester transfer (or transthioleation) (6-8). The resulting E2~Ub thioester intermediate then functions with a wide array of E3 ligases that define substrate specificity and catalyze Ub/Ubl conjugation to target proteins through a variety of mechanisms (9-13).

So-called ‘canonical’ Ub/Ubl E1 enzymes, such as those for the Ub, SUMO, and NEDD8 conjugation cascades, are defined by a conserved multi-domain structure in which each domain plays a distinct role in their catalytic cycle (14-17). Active and inactive adenylation domains (AAD and IAD, respectively) specifically recognize and adenylate the C-terminus of their cognate Ub/Ubl prior to thioester bond formation (14-17). The Cys domain, which is split into first and second catalytic cysteine half domains (FCCH and SCCH, respectively), harbors the catalytic cysteine residue that forms the thioester bond with Ub/Ubl (14-17). Finally, the ubiquitin-fold domain (UFD) of a canonical E1 is involved in molecular recognition of its cognate E2(s), which is followed by E1-E2 thioester transfer and formation of the E2~Ub thioester intermediate (17-20).

In all structures of canonical E1s determined with their respective cognate Ub/Ubl noncovalently bound to the adenylation domains, the SCCH domain adopts an ‘open’ conformation in which the catalytic cysteine that serves as the nucleophile during thioester bond formation is located more than 30 Å away from C-terminus of the Ub/Ubl (14-16,18-22). Recent structural and biochemical studies revealed that SUMO E1 has a single active site that is reconfigured for catalysis of adenylation or thioester bond formation via a series of complementary conformational changes in several regions of the E1 (21). Following adenylation of SUMO, contacts to ATP•Mg are released, facilitating a 130-degree closure of the SUMO E1 SCCH domain (termed domain alternation) and remodeling of several other structural elements that comprise the catalytic machinery of the adenylation active site (21). As a result, more than half of the residues that promote adenylation are replaced with residues that promote thioester bond formation, and the E1 catalytic cysteine is brought into proximity of the SUMO C-terminus (21). The concomitant disassembly of the adenylation active site and assembly of the thioester bond formation active site thereby toggles the catalytic competency of the active site, serving as a mechanism to drive the SUMO activation process forward. While other canonical E1 enzymes such as Ub E1 (Uba1) and NEDD8 E1 are predicted to undergo similar conformational changes during activation of their

respective Ub/Ubl (21,23,24), there is currently a lack of structural data proving this hypothesis.

In this study, we present the first crystallographic snapshot of Uba1 in which its SCCH domain has undergone a domain alternation. Comparison of our structure to previously determined Uba1 structures reveals a ~106 degree rotation of the SCCH domain and remodeling of several elements within the adenylation active site that are crucial for catalysis. Comparative structural analysis reveals that the observed conformational changes in Uba1 are analogous to those required for adenylation and thioester bond catalysis by SUMO E1. Altogether, our structural and biochemical data suggest that domain alternation and remodeling of the adenylation active site are interconnected and intrinsic structural features of Uba1, and that the structural basis for adenylation and thioester bond formation involving SCCH domain alternation and active site remodeling exhibited by SUMO E1 is indeed conserved in Uba1.

## RESULTS AND DISCUSSION

### *Structure determination and characterization of an S. pombe Uba1/NSC624206 co-complex*

NSC624206 is a Ub E1 inhibitor that specifically inhibits thioester bond formation between Ub and Uba1 without affecting adenylation activity (25) and the initial goal of this study was to elucidate the molecular mechanism by which NSC624206 inhibits Ub E1 activity. Given the disulfide bond present within NSC624206, Ungermannova et al. concluded that the mechanism of inhibition is through covalent attachment of one ‘fragment’ of NSC624206 to the Uba1 catalytic cysteine via disulfide bond, thereby abolishing its reactivity, with the other ‘fragment’ serving as a leaving group during adduct formation (25). Thus, we used a Uba1 construct harboring a catalytic cysteine to alanine substitution (C593A) in our crystallographic studies in order to prevent adduct formation between Uba1 and NSC624206, thereby allowing us to potentially identify the Uba1 binding site for intact inhibitor.

We obtained diffracting crystals of an *S. pombe* Uba1/NSC624206 co-complex in a crystal form distinct from that of any published Uba1 structure and collected a complete data set to 2.79 Å (Table 1). Initial efforts to solve the structure by molecular replacement using existing Uba1

structures as the search models failed. Deletion of the SCCH domain from the search model yielded a molecular replacement solution and inspection of the resulting maps revealed clear electron density for the SCCH domain in a drastically different conformation compared to other Uba1 structures (Figs. 1A and B). A subsequent multi-domain molecular replacement approach resulted in successful placement of the SCCH domain (Fig. 1B) and the resulting structure (hereafter referred to as Uba1<sup>SCCH\_ALT</sup>) was refined to R/Rfree values of 0.206/0.240 (Table 1).

The final Uba1<sup>SCCH\_ALT</sup> structure contains Uba1 residues 37-769 and 794-1012 and one ordered sulfate ion in a position that approximates where the  $\alpha$ -phosphate of ATP normally binds Uba1. The only unaccounted for electron density in the maps was within a deep pocket on the IAD at the 'bottom' of the Uba1 (Fig. 2A, right) and projecting off of the C994 side chain on the UFD (Fig. 2A left). We were able to place the entire NSC624206 molecule into the electron density associated with the IAD (Fig. 2A, right). With regards to the site proximal to the UFD, since the electron density projects from the sulfhydryl group of C994 we surmised that the electron density belongs to the 2-(decylamino)ethanethiol fragment of NSC624206 (Figs. 2A and B) which formed a disulfide linked adduct to C994, with the (4-chlorophenyl)methanethiol fragment of NSC624206 serving as the leaving group.

We next performed a series of biochemical experiments to determine whether the interactions between NSC624206 and Uba1 that we observe in our structure are related to the inhibitory mechanism (Figs. 2D and E). First, to test whether binding of NSC624206 to the IAD as observed in our structure plays a role in its ability to inhibit Uba1, we analyzed the detailed intermolecular interactions (Fig. 2C) and generated Uba1 G307W and S132E Uba1 mutants designed to block NSC624206 from binding to the IAD and subjected these mutants to Uba1~Ub thioester formation assays. The results of these experiments show that these mutations do not have an effect on the ability of NSC624206 to inhibit Uba1 activity (Fig. 2E). Since the UFD is involved in recruitment of E2 to Uba1 during the next step of the Ub conjugation cascade (i.e. transfer of Ub from Uba1 to the E2 catalytic cysteine), we wondered whether adduct formation

between C994 of the UFD and the 2-(decylamino)ethanethiol fragment of NSC624206 might inhibit thioester transfer of Ub from E1 to E2 due to steric occlusion of the incoming E2. To test this, we used a single turnover experiment in which fully charged Uba1 was treated with apyrase (to prevent further Uba1~Ub thioester formation) and NSC624206 followed by addition of E2 and monitoring formation of the E2~Ub product. The results of this single turnover E1-E2 Ub thioester transfer experiment indicate that treatment of Uba1 with NSC624206 does not inhibit the E1-E2 Ub thioester transfer step (Fig. 2D). This could be because the C994-2-(decylamino)ethanethiol adduct does not form on the time scale of the assay, which is on the order of minutes compared to days with the crystallization experiments, or that C994-2-(decylamino)ethanethiol adduct formation does not inhibit E2 binding. Based on: 1) the above biochemical data (Figs. 2D and E), 2) the NSC624206 binding sites on Uba1 which are distant from the Uba1 active site (Fig. 2A), 3) the involvement of NSC624206 and the 2-(decylamino)ethanethiol fragment in crystal contacts (Fig. 2C), and 4) the proposed mechanism by which NSC624206 inhibits Uba1 activity (25), we conclude that the inhibitor binding sites observed in our structure are not related to NSC624206's mechanism of inhibition, but rather that NSC624206 served as a chemical additive that facilitated crystallization and x-ray diffraction.

#### *Domain alternation and active site remodeling in *S. pombe* Uba1*

To date, five crystal structures of Uba1 have been reported in which all nine copies of Uba1 are observed with the SCCH domain in the open conformation with the catalytic cysteine 34-37 Å away from the C-terminus of Ub (14,19,20,22). Although previous studies suggest that the structural basis for catalysis of thioester bond formation by Uba1 is conserved with SUMO E1 and involves domain alternation and active site remodeling (21), there is a lack of structural evidence supporting this hypothesis.

Comparison of the Uba1<sup>SCCH\_ALT</sup> structure to previous Uba1 structures with the SCCH domain in the open conformation (hereafter referred to as Uba1<sup>SCCH\_OPEN</sup>) (14,19,20,22) reveals that the SCCH domain has undergone a domain

alternation defined by a 106 degree rigid body rotation that translocates the catalytic cysteine residue (Cys593) 34 Å (Fig. 1A). Significant conformational changes accompanying SCCH domain alternation are also observed in the crossover and reentry loops that tether the SCCH domain to the AAD (Figs. 3A-C) with the greatest structural changes in the crossover loop occurring at positions S578, Y579, G580, S581, and S582; and the greatest changes in the reentry loop occurring at positions K850, I851, and A854. Consistent with our structural observations, a previous study demonstrated that a K850P mutation in Uba1 significantly diminishes Uba1~Ub thioester bond formation (21), presumably by hindering conformational flexibility required for SCCH domain alternation.

Also similar to the case for SUMO E1, comparison of the Uba1<sup>SCCH\_ALT</sup> and Uba1<sup>SCCH\_OPEN</sup> structures reveals remodeling of several elements of the adenylation active site (Figs. 3A and C). The N-terminal helices of Uba1 (H1 and H2), which harbor residues crucial for adenylation including R22 that coordinates the  $\gamma$ -phosphate of ATP (20-22), become disordered in the Uba1<sup>SCCH\_ALT</sup> structure (Figs. 3A and C). In addition to promoting disassembly of the adenylation active site, disordering of Uba1 H1 and H2 is necessary to accommodate domain alternation of the SCCH domain as major steric clashes would occur in the absence of conformational changes in these helices, in particular between H20, H28, and the reentry loop of the SCCH domain, and H1 and H2 of the IAD. Additional elements of the adenylation active site observed to undergo remodeling in the Uba1<sup>SCCH\_ALT</sup> structure include the  $3_{10}$  helix g7 (Figs. 3A and C), which harbors residues N471, L472 and R474 known to play a key role in adenylation (21). In the Uba1<sup>SCCH\_ALT</sup> structure, g7 projects away from the ATP•Mg binding site, positioning residues involved in catalysis such that they are incapable of interacting with ATP•Mg. Further, a change in the relative angle of helix H17 of the AAD (Fig. 3C) positions residues L536, N538, and A541 such that they are incompatible with ATP binding due to major steric clashes that would occur. D537, which is involved in Mg<sup>2+</sup> coordination and is essential for Uba1 activity is also positioned suboptimally in the Uba1<sup>SCCH\_ALT</sup> structure.

Importantly, the changes observed in the adenylation active site are unique to the Uba1<sup>SCCH\_ALT</sup> structure as each of these elements adopt similar conformations in all Uba1<sup>SCCH\_OPEN</sup> structures. Taken together with the fact that the Uba1<sup>SCCH\_ALT</sup> structure was determined in the absence of Ub/ATP•Mg and does not harbor a suicide inhibitor designed to trap the tetrahedral intermediate generated during E1~Ub thioester bond formation such as 5'-(vinylsulfonylaminodeoxy)adenosine (AVSN) (21), our observations suggest that domain alternation and remodeling of the adenylation active site are interconnected and intrinsic structural features of Uba1 that do not require substrate binding and catalysis to occur. Thus, it is likely that the open and closed conformations of Uba1 exist in equilibrium in the absence of ATP•Mg and Ub. Our structural observations are consistent with a model in which ATP binding to Uba1 promotes assembly of the adenylation active site including ordering of helices H1 and H2 which shifts the equilibrium to the open state due to clashes between the SCCH domain and H1/H2 that would occur when the adenylation active site is assembled. As noted previously, the release of pyrophosphate after adenylation of the Ub C-terminus (the rate determining step of the reaction (4)) promotes disorder of H1/H2 helices, which shifts the open/closed SCCH equilibrium in the closed direction, which is required for thioester bond formation (21).

#### Comparison of *S. pombe* Uba1 and SUMO E1 structures

Comparison of SUMO E1 and Uba1 structures reveals similar overall open conformations in which the catalytic cysteine is separated from the Ubl C-terminus by 34-37 Å. Although the extent of the SCCH domain alternation differs slightly between the SUMO E1<sup>SCCH\_CLOSED</sup> and Uba1<sup>SCCH\_ALT</sup> structures (130 and 106 degrees, respectively), the general features of the rigid body rotation are similar, including the direction of the rotation and the regions in the crossover and reentry loops that accommodate this conformational change (Figs. 4A-C). Notably, reentry loop residues that undergo the greatest conformational changes during SCCH domain alternation in SUMO E1 (G381 and N382) correspond to those of Uba1 (K850 and I851). On



the other hand, Uba1 crossover loop residues that undergo the greatest conformational changes during SCCH domain alternation are offset by five residues compared to those in SUMO E1, where the greatest changes are in residues K164-R168 (21). This difference is likely due to the fact that C159 and C161 of SUMO E1, which correspond to S578 and S581 of Uba1, are involved in zinc coordination, a feature unique to SUMO and Nedd8 E1s that reduces conformational flexibility in this region of the crossover loop (15,17). Although the path of the crossover loop in the Uba1<sup>SCCH\_ALT</sup> structure places the Uba1 catalytic cysteine ~23 Å from the where the C-terminus of Ub would be located (Figs. 4A and C), in the context of the observed SCCH domain alternation, C593 can be positioned proximal to the electrophilic center simply through conformational changes within the highly flexible crossover loop and melting of the alpha helix harboring C593 (H18) as in SUMO E1.

While the SCCH domains of Uba1 and SUMO E1 harbor a conserved globular core, there are several unique structural features of the Uba1 SCCH domain that are worth noting in the context of the slight difference in the extent of SCCH domain rotation observed in the Uba1<sup>SCCH\_ALT</sup> and SUMO E1<sup>SCCH\_CLOSED</sup> structures. First, the H24-H25 loop of Uba1 harbors an eleven-residue insertion compared to the corresponding loop of SUMO E1 (the H9-H10 loop) (Fig. 4D). Further, H21 and H22 are unique to Uba1 as the corresponding region of SUMO E1 SCCH lacks helicity and is disordered in all available structures (Fig. 4D). Modeling the Uba1 SCCH domain in the precise conformation observed in the SUMO E1<sup>SCCH\_CLOSED</sup> structure reveals that the unique H24-H25 loop and H21/H22 insertions of Uba1 would severely clash with the AAD and IAD, respectively (Fig. 4D). This suggests that the magnitude of SCCH domain alternation required for thioester bond formation in Uba1 and SUMO E1 is unlikely to be precisely the same. With that said, the SCCH domain extensively covers the SUMO E1 active site in the closed conformation, including contacts between the H9-H10 loop and the AAD (Fig. 4B); whereas in the Uba1<sup>SCCH\_ALT</sup> structure, the SCCH domain less extensively covers the active site and the H24-H25 loop does not engage in contacts to the AAD (Fig. 4A). Whether this reflects actual differences in the *bona*

*fide* Uba1<sup>SCCH\_CLOSED</sup> structure or indicates the need for a slight additional rotation of the SCCH domain compared to what we observe in the Uba1<sup>SCCH\_ALT</sup> structure awaits structural characterization of the tetrahedral intermediate formed during E1~Ub thioester bond formation. This slight additional rotation of the SCCH domain (if necessary) could easily be achieved through the additional conformational changes in the flexible crossover and reentry loops necessary to properly position the catalytic cysteine for nucleophilic attack during thioester bond formation.

#### *Domain alternation results in distinct networks of intramolecular contacts between the SCCH domain and other Uba1 domains*

While a total of ~2300 Å<sup>2</sup> surface area is buried at the intramolecular interface between the SCCH domain and the AAD, IAD, and FCCH domain in Uba1<sup>SCCH\_OPEN</sup> structures, SCCH domain alternation and the resulting network of unique intramolecular interactions increases this value to ~3200 Å<sup>2</sup> in the Uba1<sup>SCCH\_ALT</sup> structure (Figs. 5A and B). Interestingly, while there are relatively few contacts between the FCCH and SCCH domains in Uba1<sup>SCCH\_OPEN</sup> structures, the buried surface at the interface between these two domains nearly doubles (~700 Å<sup>2</sup>) in Uba1<sup>SCCH\_ALT</sup> (Fig. 5A). Specifically, during SCCH domain alternation a highly conserved salt bridge between E214 of the FCCH domain and R707 of the SCCH domain observed in Uba1<sup>OPEN</sup> structures is broken and a completely different network of contacts forms including a salt bridge between E179 of the FCCH domain and K812 of the SCCH domain (Fig. 5B, right panels). Additionally, F842 of the SCCH domain inserts into a hydrophobic patch on the FCCH domain formed by T182, M184, and V235. This suggests that rather than being conformationally flexible upon SCCH domain alternation, the FCCH domain of Uba1 may contribute to thioester bond formation by stabilizing the SCCH closed conformation via the formation of these additional intramolecular contacts. While T182 does not form any intramolecular contacts in the Uba1<sup>SCCH\_OPEN</sup> structure, it does form the aforementioned contact with F842 in the Uba1<sup>SCCH\_ALT</sup> structure. A T182E mutation results in a very slight decrease in Ub adenylate formation, but modestly increases

E1~Ub thioester formation (Fig. 5C). The larger, charged glutamic acid side chain can presumably form more contacts with residues in the SCCH, which would further support the idea that the FCCH domain stabilizes the SCCH closed conformation during thioester transfer. Notably, this appears to be a feature unique to Uba1 as the FCCH domain of SUMO E1 is significantly smaller and largely disordered in all SUMO E1 structures, including SUMO E1<sup>SCCH\_CLOSED</sup> (15,21) (Fig. 4B).

Domain alternation also results in a completely different network of intramolecular interactions between the SCCH domain and IAD/AAD in the Uba1<sup>SCCH\_ALT</sup> structure, with most changes occurring around the Uba1 active site. A total of ~850 Å<sup>2</sup> of surface area are buried at the interface between the SCCH and AAD/IAD in Uba1<sup>SCCH\_OPEN</sup> structures, most of which (~650 Å<sup>2</sup>) involve H1 and H2 of the IAD that become disordered in the Uba1<sup>SCCH\_ALT</sup> structure (Figs. 5A and B). The H1 and H2 active site remodeling that occurs during SCCH domain alternation significantly affects inter-domain contacts in this region. N473 of the AAD, located on helix g7, forms a hydrogen bond with Q23 of helix H1 in the Uba1<sup>SCCH\_OPEN</sup> structure, but also forms contacts with Q105 and Y106 in the Uba1<sup>SCCH\_ALT</sup> structure (Fig. 5B, left panels). As expected, an N473E mutation decreases both adenylation and E1~Ub thioester formation activity compared to WT (Fig. 5C), confirming this residue's role in domain stabilization in both the open and closed conformations.

Other notable interactions resulting from domain alternation involve S641 and S642 of the SCCH domain, which engage in hydrogen bonds to Q105 of the IAD and K469 of the AAD, respectively. Q619, D622, and N623 of the SCCH are also brought in proximity to Y106 of the AAD where a network of van der Waals interactions takes place (Fig. 5B, left panels). Consistent with these observations, a Q105E/Y106E double mutant, which disrupts a major set of interactions in the Uba1<sup>SCCH\_ALT</sup> structure but should not have any consequence based on the Uba1<sup>SCCH\_OPEN</sup> structure, has no effect on Ub adenylation, but it does show a 2-fold decrease in Uba1~Ub thioester formation (Fig. 5C), suggesting a defect specifically at the thioester bond formation step of Ub activation. Additionally, in the

Uba1<sup>SCCH\_OPEN</sup> structure, D813 from the SCCH domain forms a salt bridge with R22 from the IAD, which contacts the γ-phosphate of ATP; however, in the Uba1<sup>SCCH\_ALT</sup> structure, D813 contacts K376 from the IAD domain and P180 from the FCCH domain (Fig 5B, right panels). A D813A mutation does not have an effect on adenylation activity but does result in a loss of E1~Ub thioester formation (Fig. 5C). Thus, the contacts between D813 and specific residues in the IAD and FCCH domains could be important for stabilizing the E1 during SCCH alternation during thioester bond formation. Finally, a D537A Uba1 mutant that is known to lack catalytic activity due to an inability to coordinate a magnesium ion necessary for adenylation was used as a negative control for the adenylation and thioester formation assays (Fig. 5C).

## CONCLUSIONS

In this manuscript we have presented the first crystallographic snapshot of Uba1 in which SCCH domain alternation and active site remodeling has been observed. Although precise details await determination of a *bona fide* Uba1~Ub-AMP tetrahedral intermediate structure, our Uba1<sup>SCCH\_ALT</sup> structure provides the first structural evidence that the salient features of thioester bond formation by Uba1 are shared with SUMO E1. Our data suggest that SCCH domain alternation and active site remodeling are interconnected and intrinsic structural features of Uba1 and that the open and closed conformations of Uba1 exist in equilibrium prior to ATP•Mg and Ub binding. Our structural observations, together with previous data are consistent with a model in which ATP binding to Uba1 shifts the equilibrium to an open state (adenylation active) and that pyrophosphate release after adenylation shifts the equilibrium to the closed state (thioester active). Finally, the insights provided by the novel conformational snapshot of Uba1 presented in this study may guide efforts to develop small molecule inhibitors of this critically important enzyme that is an active target for anti-cancer therapeutics.

## EXPERIMENTAL PROCEDURES

*Protein expression, purification, and crystallization*—Wild-type (WT) and mutated variants of full-length (residues 1-1012) *S. pombe* Uba1, *S. pombe* Ubc4 and *S. pombe* Ub (residues

1-76) used in structural and biochemical studies were expressed in *E. coli* and purified as previously described (19). Purified proteins were concentrated to ~25 mg/ml (Uba1 WT and variants) or ~10 mg/ml (Ub) and snap frozen in liquid nitrogen for use in subsequent crystallization and biochemical experiments. The sample used for crystallization and subsequent determination of the Uba1<sup>SCCH\_ALT</sup> structure was obtained by mixing Uba1<sup>C593A</sup> mutant protein (177  $\mu$ M final), the Uba1 inhibitor NSC624206 (1 mM final from a 50 mM stock in 100% DMSO; Tocris Bioscience), and MgCl<sub>2</sub> (5 mM final). Following a 30 minute incubation on ice, 1  $\mu$ l of the Uba1<sup>C593A</sup>/NSC624206/MgCl<sub>2</sub> mixture (in 20 mM Tris pH 8.0, ~250 mM NaCl buffer) was added to 1  $\mu$ l crystallization buffer (80 mM sodium citrate pH 5.9, 1 M ammonium sulfate) followed by hanging drop vapor diffusion at 15°C. Reducing agent was omitted in order to maintain the integrity of NSC624206, which contains a disulfide bond. Uba1<sup>SCCH\_ALT</sup> crystals grew to maximum size in two weeks and were flash-frozen in liquid nitrogen following cryoprotection in an 80 mM sodium citrate pH 5.9 and 4 M ammonium sulfate solution.

*X-ray data collection, structure determination, and refinement*—A complete data set for the Uba1<sup>SCCH\_ALT</sup> crystals was collected to a resolution of 2.79 Å at the Advanced Photon Source (Argonne, Illinois, USA), SER-CAT beamline 22-ID. All data were indexed, integrated, and scaled using HKL2000 (26). The Uba1<sup>SCCH\_ALT</sup> crystals belong to space group P2<sub>1</sub>3 with unit cell dimensions  $a=b=c=145.1$  Å and there is one molecule of Uba1 per asymmetric unit. Initial molecular replacement efforts using complete existing Uba1 structures as search models failed. A search model comprising Uba1 from the *S. pombe* Uba1/Ub/ATP•Mg complex (PDB: 4II3) (20) with the SCCH domain deleted yielded a successful molecular replacement solution using the program PHASER (27). After one round of refinement, the resulting maps were inspected and clear electron density for the SCCH domain in a conformation significantly different than in previous structures was evident. A subsequent multiple ensemble molecular replacement search comprising 1) the previous molecular replacement solution and 2) the standalone SCCH domain

resulted in successful placement of the SCCH domain into the appropriate electron density. The model was refined to R/Rfree values of 0.206/0.240 via iterative rounds of refinement and rebuilding using PHENIX (28) and COOT (29). All molecular graphics representations of the structures were generated using PyMOL (30).

The final Uba1<sup>SCCH\_ALT</sup> structure contains Uba1 residues 37-769 and 794-1012 and there is one ordered sulfate ion in a position that approximates where the  $\alpha$ -phosphate of ATP normally binds Uba1. As detailed in the main text, electron density for an intact NSC624206 inhibitor noncovalently bound to the Uba1 IAD, as well as a 2-(decylamino)ethanethiol fragment of NSC624206 that formed a disulfide linked adduct to C994 of UFD was evident (also see Figs. 2A-C).

*ATP:PPi Isotope Exchange Assays*—Radioactive isotope-based ATP:PPi exchange assays were adapted from previous work (31,32). 50- $\mu$ l reaction mixtures containing 50 mM Tris, pH 7.5, 10 mM MgCl<sub>2</sub>, 0.5 mM DTT, 1 mM ATP, 1 mM [<sup>32</sup>P]PPi (PerkinElmer Life Sciences), and 10  $\mu$ M Ub were incubated with 0.2  $\mu$ M WT or mutant E1 proteins at 37°C for 20 min before the reaction was quenched with 5% (w/v) trichloroacetic acid (0.5 ml) containing 4 mM carrier PPi. After processing, data were quantitated by Cerenkov counting.

*Uba1~Ub Thioester Formation Assays*—Uba1~Ub thioester formation assays for wild type and mutant proteins were performed in a reaction containing 50 nM Uba1, 2  $\mu$ M Ub, 5 mM MgCl<sub>2</sub>, 20 mM MES pH 5.5, 50 mM NaCl, and 2  $\mu$ M ATP. Reactions were incubated for 5 seconds at 4°C. For inhibitor mediated thioester-transfer assays, 1  $\mu$ M, 20  $\mu$ M, or 1 mM of the NSC624206 inhibitor was added to the reactions, which were then incubated for 30 seconds at room temperature. To account for DMSO required to solubilize NSC624206, 5% DMSO was included in all assays involving inhibitor. After incubation, all reactions were denatured in non-reducing SDS-PAGE buffer and subjected to SDS-PAGE. The gels were stained with Sypro Ruby (BioRad) and visualized with a ChemiDoc MP (BioRad).

**Acknowledgements:** Atomic coordinates and structure factors are deposited in the RCSB with accession code 5UM6. The authors thank Christopher Davies and Katelyn Williams for critically reading the manuscript. Research reported in this publication was supported by NIH R01 GM115568 (SKO) and NIH R01 CA088932 (YC). This work was also supported in part by the Hollings Cancer Center's T32 Ruth L. Kirschstein National Research Service Award Training Program T32 CA193201 (JA). This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P41 GM103403). The Pilatus 6M detector on 24-ID-C beam line is funded by a NIH-ORIP HEI grant (S10 RR029205). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. This work is also based upon research conducted at SER-CAT beamline 22-ID. The X-ray crystallography facility used for this work is supported by Office of the Vice President for Research at the Medical University of South Carolina. The crystallization robotics instrument used in this study was purchased via an NIH Shared Instrumentation Award (S10 RR027139-01). The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Correspondence and requests for materials should be addressed to SKO (olsenskm@musc.edu).

**Conflict of Interest:** The authors declare that they have no conflict of interest with the contents of this article.

**Author Contributions:** Structural and biochemical experiments were performed by ZL, GA, and SKO. Data were analyzed by ZL, LY, JHA, GA, YC, and SKO. The manuscript was prepared by ZL, JHA, YC, and SKO.

## REFERENCES

1. Komander, D., and Rape, M. (2012) The ubiquitin code. *Annu Rev Biochem* **81**, 203-229
2. van der Veen, A. G., and Ploegh, H. L. (2012) Ubiquitin-like proteins. *Annu Rev Biochem* **81**, 323-357
3. Hochstrasser, M. (2009) Origin and function of ubiquitin-like proteins. *Nature* **458**, 422-429
4. Haas, A. L., and Rose, I. A. (1982) The mechanism of ubiquitin activating enzyme. A kinetic and equilibrium analysis. *J Biol Chem* **257**, 10329-10337
5. Haas, A. L., Warme, J. V., Herskko, A., and Rose, I. A. (1982) Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. *J Biol Chem* **257**, 2543-2548
6. Haas, A. L., Bright, P. M., and Jackson, V. E. (1988) Functional diversity among putative E2 isozymes in the mechanism of ubiquitin-histone ligation. *J Biol Chem* **263**, 13268-13275
7. Herskko, A., Heller, H., Elias, S., and Ciechanover, A. (1983) Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. *J Biol Chem* **258**, 8206-8214
8. Pickart, C. M., and Rose, I. A. (1985) Functional heterogeneity of ubiquitin carrier proteins. *J Biol Chem* **260**, 1573-1581
9. Hanzelmann, P., Schafer, A., Voller, D., and Schindelin, H. (2012) Structural insights into functional modes of proteins involved in ubiquitin family pathways. *Methods Mol Biol* **832**, 547-576



10. Berndsen, C. E., and Wolberger, C. (2014) New insights into ubiquitin E3 ligase mechanism. *Nat Struct Mol Biol* **21**, 301-307
11. Schulman, B. A., and Harper, J. W. (2009) Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. *Nat Rev Mol Cell Biol* **10**, 319-331
12. Stewart, M. D., Ritterhoff, T., Klevit, R. E., and Brzovic, P. S. (2016) E2 enzymes: more than just middle men. *Cell Res* **26**, 423-440
13. Streich, F. C., Jr., and Lima, C. D. (2014) Structural and functional insights to ubiquitin-like protein conjugation. *Annu Rev Biophys* **43**, 357-379
14. Lee, I., and Schindelin, H. (2008) Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. *Cell* **134**, 268-278
15. Lois, L. M., and Lima, C. D. (2005) Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. *EMBO J* **24**, 439-451
16. Walden, H., Podgorski, M. S., Huang, D. T., Miller, D. W., Howard, R. J., Minor, D. L., Jr., Holton, J. M., and Schulman, B. A. (2003) The structure of the APPBP1-UBA3-NEDD8-ATP complex reveals the basis for selective ubiquitin-like protein activation by an E1. *Mol Cell* **12**, 1427-1437
17. Walden, H., Podgorski, M. S., and Schulman, B. A. (2003) Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. *Nature* **422**, 330-334
18. Huang, D. T., Hunt, H. W., Zhuang, M., Ohi, M. D., Holton, J. M., and Schulman, B. A. (2007) Basis for a ubiquitin-like protein thioester switch toggling E1-E2 affinity. *Nature* **445**, 394-398
19. Lv, Z., Rickman, K. A., Yuan, L., Williams, K., Selvam, S. P., Woosley, A. N., Howe, P. H., Ogretmen, B., Smogorzewska, A., and Olsen, S. K. (2017) S. pombe Uba1-Ubc15 Structure Reveals a Novel Regulatory Mechanism of Ubiquitin E2 Activity. *Mol Cell* **65**, 699-714 e696
20. Olsen, S. K., and Lima, C. D. (2013) Structure of a ubiquitin E1-E2 complex: insights to E1-E2 thioester transfer. *Mol Cell* **49**, 884-896
21. Olsen, S. K., Capili, A. D., Lu, X., Tan, D. S., and Lima, C. D. (2010) Active site remodelling accompanies thioester bond formation in the SUMO E1. *Nature* **463**, 906-912
22. Schafer, A., Kuhn, M., and Schindelin, H. (2014) Structure of the ubiquitin-activating enzyme loaded with two ubiquitin molecules. *Acta Crystallogr D Biol Crystallogr* **70**, 1311-1320
23. Brownell, J. E., Sintchak, M. D., Gavin, J. M., Liao, H., Bruzzese, F. J., Bump, N. J., Soucy, T. A., Milhollen, M. A., Yang, X., Burkhardt, A. L., Ma, J., Loke, H. K., Lingaraj, T., Wu, D., Hamman, K. B., Spelman, J. J., Cullis, C. A., Langston, S. P., Vyskocil, S., Sells, T. B., Mallender, W. D., Visiers, I., Li, P., Claiborne, C. F., Rolfe, M., Bolen, J. B., and Dick, L. R. (2010) Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. *Mol Cell* **37**, 102-111
24. Chen, J. J., Tsu, C. A., Gavin, J. M., Milhollen, M. A., Bruzzese, F. J., Mallender, W. D., Sintchak, M. D., Bump, N. J., Yang, X., Ma, J., Loke, H. K., Xu, Q., Li, P., Bence, N. F., Brownell, J. E., and Dick, L. R. (2011) Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues. *J Biol Chem* **286**, 40867-40877
25. Ungermannova, D., Parker, S. J., Nasveschuk, C. G., Chapnick, D. A., Phillips, A. J., Kuchta, R. D., and Liu, X. (2012) Identification and mechanistic studies of a novel ubiquitin E1 inhibitor. *J Biomol Screen* **17**, 421-434

26. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode. *Methods in Enzymology* **276**, 307-326
27. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. *J Appl Crystallogr* **40**, 658-674
28. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-221
29. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* **60**, 2126-2132
30. Delano, W. (2002) The PyMOL molecular graphics system. DeLano Scientific, San Carlos CA, USA. <http://www.pymol.org>.
31. Burch, T. J., and Haas, A. L. (1994) Site-directed mutagenesis of ubiquitin. Differential roles for arginine in the interaction with ubiquitin-activating enzyme. *Biochemistry* **33**, 7300-7308
32. Wang, J., Cai, S., and Chen, Y. (2010) Mechanism of E1-E2 interaction for the inhibition of Ubl adenylation. *J Biol Chem* **285**, 33457-33462

## FOOTNOTES

The abbreviations used in this work are: Ub, ubiquitin; Ubl, ubiquitin-like modifier; AAD, active adenylation domain; IAD, inactive adenylation domain; UFD, ubiquitin fold domain; FCCH, first catalytic cysteine half domain; SCCH, second catalytic cysteine half domain; Uba1<sup>SCCH\_ALT</sup>, Uba1 'closed' conformation; Uba1<sup>SCCH\_OPEN</sup>, Uba1 'open' conformation (PDB: 4II3); SUMO E1<sup>SCCH\_CLOSED</sup>, SUMO E1 'closed' conformation (PDB: 3KYD); SUMO E1<sup>SCCH\_OPEN</sup>, SUMO E1 'open' conformation (PDB: 3KYC).

## FIGURE LEGENDS

**FIGURE 1. Crystal structure of domain-alternated *S. pombe* Uba1.** (A) Comparison of the Uba1<sup>SCCH\_ALT</sup> (*left*) and Uba1<sup>SCCH\_OPEN</sup> (PDB: 4II3, *right*) structures, shown as cartoon representations. Uba1 domains are labeled and color coded and ATP and Ub(a) from the Uba1<sup>SCCH\_OPEN</sup> structure are shown as spheres and a yellow cartoon, respectively. Catalytic cysteines positions (Cys593) are indicated with an arrow and the SCCH domain alternation is highlighted by a double-headed arrow. (B) Cartoon representations of the Uba1<sup>SCCH\_ALT</sup> (*left*) and Uba1<sup>SCCH\_OPEN</sup> (*right*) structures overlaid with the 2Fo-Fc electron density (green) for the SCCH domain of the Uba1<sup>SCCH\_ALT</sup> structure. For clarity, the SCCH domain of the Uba1<sup>SCCH\_ALT</sup> structure is shown as loops. The Uba1 domains, ATP, and Ub(a) are colored and labeled as in A.

**FIGURE 2. Interactions between the Uba1<sup>SCCH\_ALT</sup> and NSC624206.** (A) (*middle*) The Uba1<sup>SCCH\_ALT</sup> structure is shown as a surface representation in two orientations and the NSC624206 compound noncovalently bound to the IAD and the 2-(decylamino)ethanethiol fragment covalently bound to the UFD via disulfide bond are shown as sticks. The domains are colored and labeled as in Figure 1. (*left*) Magnified view of the 2-(decylamino)ethanethiol fragment of NSC624206, shown as sticks, bound to the UFD. Omit 2Fo-Fc electron density for the fragment is shown in green. The UFD and AAD are shown as surface representations and residues that form contacts with the fragment are colored and labeled. (*second from left*) Magnified view of the 2-(decylamino)ethanethiol fragment, shown as sticks, bound to C994 of the UFD, shown as a cartoon representation. Side chains of residues that form contacts with the fragment are shown as sticks and labeled. The AAD is shown as a surface representation. (*second from right*) Magnified view of the NSC624206 compound, shown as sticks, bound to the IAD, shown as a cartoon representation. Side chains of residues that form contacts with the compound are shown as sticks and labeled. The IAD and SCCH are shown as surface representations. (*right*) Magnified view of the NSC624206 compound, shown as sticks, bound to the IAD. Omit 2Fo-Fc electron density for the compound is shown in green. The IAD is shown as a surface representation and residues that form contacts with the fragment are colored and labeled. (B) Chemical structures of the NSC624206 compound and the 2-(decylamino)ethanethiol fragment. (C) Crystal contacts with the NSC624206 compound. (*top*) The Uba1<sup>SCCH\_ALT</sup> structure is shown as a cartoon representation in two different orientations and the domains are colored and labeled as in A. Symmetry mates that form contacts with the 2-(decylamino)ethanethiol fragment, shown as sticks, bound to the UFD (*left*) and to the NSC624206 compound, shown as sticks, bound to the IAD (*right*) are also shown as semitransparent cartoon representations with the domains colored and labeled. (*bottom*) Magnified views of the 2-(decylamino)ethanethiol fragment bound to the UFD (*left*) and NSC624206 compound bound to the IAD (*right*). The side chains of residues from Uba1<sup>SCCH\_ALT</sup> and the symmetry mates that form contacts with the fragment or compound are shown as sticks and labeled. (D) Biochemical analysis of the effect of 2-(decylamino)ethanethiol modification on UFD Cys994. An E1-E2 single turnover thioester transfer assay from Uba1 to Ubc4 was performed with different concentrations of NSC624206 or DMSO. (See Experimental Procedures for details). (E) Biochemical analysis of the inhibitory effect of NSC624206 on WT and mutant Uba1 activity. Uba1~Ub thioester formation assays were performed as readouts of Uba1 catalytic activity with different concentrations of NSC624206 or DMSO (See Experimental Procedures for details).

**FIGURE 3. Active site remodeling in *S. pombe* Uba1.** (A) Conformational changes in the crossover and reentry loops upon SCCH domain alternation. (*top*) Uba1 from the Uba1<sup>SCCH\_ALT</sup> and Uba1<sup>SCCH\_OPEN</sup> structures are shown as a surface representation with indicated domains colored various shades of gray. Ub(a) from the Uba1<sup>SCCH\_OPEN</sup> structure is shown as a gold cartoon. The crossover and reentry loops are shown as putty representations and the diameter and color (see color code above structures) of the putty correspond to the sum of the absolute change in phi and psi angles. (*bottom*) Active site remodeling

accompanies Uba1 SCCH domain alternation. The Uba1<sup>SCCH\_ALT</sup> (*left*) and Uba1<sup>SCCH\_OPEN</sup> (*right*) structures are shown in the same orientation as cartoon representations with domains colored as in the top panels. Regions undergoing conformational changes in the Uba1 active site upon SCCH domain alternation are color coded and labeled. H1 and H2 of Uba1 that become disordered in the Uba1<sup>SCCH\_ALT</sup> structure are shown as semitransparent slate spheres. The alpha carbons of the residues that undergo significant changes between the open and closed conformations are labeled and shown as spheres. (B) Differences in phi and psi angles for residues in the crossover and reentry loops between the Uba1<sup>SCCH\_ALT</sup> and Uba1<sup>SCCH\_OPEN</sup> structures were calculated and plotted. (C) The adenylation domains of the Uba1<sup>SCCH\_ALT</sup> and Uba1<sup>SCCH\_OPEN</sup> structures were superimposed and are shown as cartoon representations. ATP from the Uba1<sup>SCCH\_OPEN</sup> structure is shown as spheres. Note that this panel is presented in a top-down view, which differs from the front views presented in panel A in order to better highlight the conformational changes that occur during active site remodeling and SCCH domain alternation in the context of the superimposed structures.

**FIGURE 4. Comparison of Uba1 and SUMO E1 in different conformational states.** (A) The Uba1<sup>SCCH\_OPEN</sup> (*left*) and Uba1<sup>SCCH\_ALT</sup> (*right*) structures are shown as surface representations (with the exception of the SCCH domain, which is shown as a light magenta cartoon) with domains color-coded and labeled. Ub(a) and ATP were modeled onto the Uba1<sup>SCCH\_ALT</sup> structure based on how they interact with Uba1 in the Uba1<sup>SCCH\_OPEN</sup> structure. SCCH domain helices are labeled and the N- and C-terminal ends of the helices are indicated to facilitate structure comparison. H18 and H19 of the Uba1 structures are colored red to correspond with H6 and H7 of the SUMO E1 structures in B. H29 of the Uba1 structures is colored cyan to correspond with H13 of the SUMO E1 structures in B. The approximate direction of the SCCH domain alternation is indicated with a double-headed arrow. A magnified view of the Uba1<sup>SCCH\_ALT</sup> active site is shown in the right inset. (B) The SUMO E1<sup>SCCH\_OPEN</sup> (PDB ID: 3KYC) and SUMO E1<sup>SCCH\_CLOSED</sup> (PDB ID: 3KYD) structures are presented in the same style and orientation as Uba1 in A. (C) Comparison of the crossover/reentry loops and SCCH domains of the Uba1<sup>SCCH\_OPEN</sup> (PDB ID: 4I13) and SUMO E1<sup>SCCH\_OPEN</sup> (PDB ID: 3KYC) structures (*bottom*) and the Uba1<sup>SCCH\_ALT</sup> and SUMO E1<sup>SCCH\_CLOSED</sup> (PDB ID: 3KYD) structures (*top*). The adenylation domains of the structures were superimposed. The structures are shown as cartoon representations and ATP, AVSN (5'-(vinylsulfonylaminodeoxy)adenosine), or AMSN (5'-(sulfamoylaminodeoxy)adenosine) are shown as sticks. The difference in SCCH domain positioning in the Uba1<sup>SCCH\_ALT</sup> and SUMO E1<sup>SCCH\_CLOSED</sup> structures is indicated with a double-headed arrow. (D) (*left*) Comparison of the Uba1 and SUMO E1 SCCH domains. Unique structural elements of the Uba1 SCCH domain are indicated with a black dashed oval. (*right*) The Uba1 SCCH domain was docked onto Uba1 in the same orientation as the SUMO E1<sup>SCCH\_CLOSED</sup> structure. Steric clashes involving the unique structural elements of the Uba1 SCCH domain illustrate the fact that the extent of domain alternation in Uba1 and SUMO E1 during thioester bond formation is unlikely to be precisely the same.

**FIGURE 5. A unique network of contacts between the Uba1 SCCH, FCCH, and AAD domains in the Uba1<sup>SCCH\_ALT</sup> structure.** (A) Uba1<sup>SCCH\_ALT</sup> (*top left*) and Uba1<sup>SCCH\_OPEN</sup> (*bottom left*) structures are shown as surface representations with domains labeled and color coded. For clarity, Ub(a) from the Uba1<sup>SCCH\_OPEN</sup> structure is not shown. The right panels show the intramolecular interface between Uba1 and the globular SCCH domain as an open book representation with residues buried at the interface shaded green. To highlight the altered network of interactions resulting from the SCCH domain alternation, SCCH residues involved in unique intramolecular interactions in the two structures are labeled. (B) Uba1<sup>SCCH\_ALT</sup> (*top*) and Uba1<sup>SCCH\_OPEN</sup> (*bottom*) structures are shown as cartoon representations with magnified views of the SCCH/AAD and SCCH/FCCH intramolecular interfaces shown in the left and right insets, respectively. Residues involved in interactions are shown as sticks and hydrogen bonds are indicated with dashed black lines. (C) Structure-function analysis of intramolecular contacts between Uba1 and the globular SCCH domain unique to the Uba1<sup>SCCH\_ALT</sup> structure. ATP:PPi exchange assays (*top*) and Uba1~Ub thioester formation assays (*bottom*) were performed as readouts of



Uba1 catalytic activities. All experiments were performed in triplicate as described in Experimental Procedures and error bars represent  $\pm 1$  standard deviation. \* $P \leq 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ ; ns=not significant.

**Table 1. Crystallographic Data and Refinement Statistics**

	<i>S. pombe</i> Uba1
PDB ID	5UM6
Source	APS 22 ID
Wavelength (Å)	1.08
Resolution Limits (Å)	50-2.79 (2.90-2.79)
Space Group	P2 <sub>1</sub> 3
Unit Cell (Å) <i>a</i> , <i>b</i> , <i>c</i>	145.1, 145.1, 145.1
Unit Cell (°) $\alpha$ , $\beta$ , $\gamma$	90, 90, 90
Number of observations	314006
Number of reflections	25520 (2515)
Completeness (%)	100.0 (100.0)
Mean <i>I</i> / $\sigma$ <i>I</i>	39.2 (3.4)
CC <sub>1/2</sub>	(0.890)
R <sub>merge</sub> <sup>a</sup>	0.066 (0.726)
R <sub>pim</sub>	0.020 (0.214)
<b>Refinement Statistics</b>	
Resolution Limits (Å)	40.2-2.79 (2.91-2.79)
# of reflections (work/free)	25461/1292
Completeness (%)	98.9 (99.0)
Protein/ligand atoms	7551/42
R <sub>cryst</sub> <sup>b</sup>	0.206 (0.274)
R <sub>free</sub> (5.1% of data)	0.240 (0.290)
Bonds (Å)/ Angles (°)	0.003/0.508
B-factors: protein/ligand (Å <sup>2</sup> )	47.9/62.1
Ramachandran plot statistics (%)	
favored	95.4
allowed	4.3
outliers	0.3
MolProbity score	1.95- 99 <sup>th</sup> percentile (N=4464, 2.79 Å ± 0.25Å)

Parentheses indicate statistics for the high-resolution data bin for x-ray data.

a.  $R_{merge} = \frac{\sum hkl \sum i |I(hkl)_i - \langle I(hkl) \rangle|}{\sum hkl \sum i \langle I(hkl) \rangle}$ .

b.  $R_{cryst} = \frac{\sum hkl |F_o(hkl) - F_c(hkl)|}{\sum hkl |F_o(hkl)|}$ , where *F<sub>o</sub>* and *F<sub>c</sub>* are observed and calculated structure factors, respectively.






Figure 1


A




B



C



D



E








Figure 2



**A** *SpUba1<sup>SCCH\_ALT</sup> structure (front view)**SpUba1<sup>SCCH\_OPEN</sup> structure (PDB: 4II3) (front view)***B**

$\Delta\phi_i/\Delta\psi_i$  values for Uba1 residues driving domain alternation of the SCCH Domain



**C**

Figure 3








Figure 5

**Domain alternation and active site remodeling are conserved structural features of ubiquitin E1**

Zongyang Lv, Lingmin Yuan, James H. Atkison, Grace Aldana-Masangkay, Yuan Chen and Shaun K. Olsen

*J. Biol. Chem.* published online June 1, 2017

---

Access the most updated version of this article at doi: [10.1074/jbc.M117.787622](https://doi.org/10.1074/jbc.M117.787622)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at <http://www.jbc.org/content/early/2017/06/01/jbc.M117.787622.full.html#ref-list-1>